David M. Jablons - Concepedia

Author

David M. Jablons

Also Known As

D Jablons, D M Jablons, D. Jablons, D. M. JABLONS, D. M. Jablons, D.M Jablons, D.M. Jablons, DAVID JABLONS, DAVID M. JABLONS, David Jablons

445

Publications

20.4K

Citations

H-Index

169

Concepts

All Affiliations

University of California, San Francisco UCSF Helen Diller Family Comprehensive Cancer Center Lawrence Berkeley National Laboratory Chang Gung Memorial Hospital Beijing Chao-Yang Hospital

About

David M. Jablons is an author at University of California, San Francisco specializing in medicine, cell biology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	92	8.8K
2	Health Sciences	11	11	822
3	Public Health	3	3	88
4	Engineering	2	2	251
5	Natural Sciences	2	2	51

David M. Jablons

177

Publications

16.7K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer David H. Johnson, Louis Fehrenbacher, William Novotny, Journal of Clinical Oncology	2004	1.9K
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing Ashley Maynard, Caroline E. McCoach, Julia Rotow, Cell	2020	666
Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion Carolyn M. Dresler, Jemi Olak, James E. Herndon, CHEST Journal UrologySclerodermaPathologyPleural EffusionTalc Poudrage	2005	574
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer Biao He, Liang You, Kazutsugu Uematsu, Proceedings of the National Academy of Sciences ImmunologyCell DeathCancer BiologyTumor BiologySignaling Pathway	2003	376
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer Bin-Bing Zhou, Michael Peyton, Biao He, Cancer Cell Tumor BiologyAdam-mediated Ligand CleavageEgfr PathwaysMedicineBronchial Neoplasm	2006	375
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas Miguel Tarón, Yukito Ichinose, Rafael Rosell, Clinical Cancer Research	2005	336
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies Johannes R. Kratz, Jianxing He, Stephen K. Van Den Eeden, The Lancet Non-small-cell Lung CancerCancer DetectionMedicinePathologyInternational Validation Studies	2012	328
Natural History of Stage I Non-Small Cell Lung Cancer Dan J. Raz, Jason A. Zell, S-H.I. Ou, CHEST Journal MedicineNatural HistoryPathologyBronchial NeoplasmPulmonary Blastoma	2007	322
Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression Kazutsugu Uematsu, Biao He, Liang You, Oncogene Tumor BiologyDishevelled OverexpressionMedicinePathologyBronchial Neoplasm	2003	315
A positive feedback between p53 and <i>miR-34</i> miRNAs mediates tumor suppression Nobuhiro Okada, Chao‐Po Lin, Marcelo C. Ribeiro, Genes & Development	2014	288

Page 1